Medical research

Tackling resistance to HIF2 drugs with an RNA-based therapy

Expected to be diagnosed in 2% of men and 1% of women in the U.S., kidney cancer has traditionally been one of the most challenging cancers to treat. Until 2005, only one drug had been approved by the Food and Drug Administration ...

Medications

ALS drug wins FDA approval despite questionable data

A much-debated drug for Lou Gehrig's disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.

Medications

ALS drug gets rare second review at high-stakes FDA meeting

A closely watched experimental drug for Lou Gehrig's disease got an unusual second look from U.S. regulators on Wednesday, following intense pressure to approve the treatment for those with the fatal illness.

Medications

FDA still skeptical of ALS drug ahead of high-stakes meeting

Federal health regulators remain unconvinced about the benefits of a closely watched experimental drug for the debilitating illness known as Lou Gehrig's disease, even as they prepare to give its drugmaker a rare second opportunity ...

Diseases, Conditions, Syndromes

Examining COVID-19 and its many sublineages

As new omicron subvariants of COVID-19 continue to sweep across the United States, researchers at the University of Missouri have identified specific mutations within the virus' spike protein that help omicron subvariants ...

Medications

Experimental ALS drug may be more effective than existing ones

New research on the experimental drug NU-9, invented and developed by two Northwestern University scientists to treat ALS (amyotrophic lateral sclerosis), shows it is more effective than existing FDA-approved drugs for the ...

page 4 from 17